The first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A in the event of a pandemic has been approved in the US.
Made by flu prevention and pandemic response specialist, Seqirus, Audenz is a novel vaccine combining two leading-edge technologies—MF59 adjuvant and cell-based antigen manufacturing.
Audenz is designed to be rapidly deployed to help protect the US population and can be stockpiled for first responders in the event of pandemic.
“The approval of Audenz represents a key advance in influenza prevention and pandemic preparedness, combining leading-edge cell-based manufacturing and adjuvant technologies,” said Russell Basser, Chief Scientist and Senior Vice President of R&D at Seqirus.
“This pandemic influenza vaccine exemplifies our commitment to developing innovative technologies that can help provide rapid response during a pandemic emergency.”
Seqirus is uniquely positioned to manufacture cell-based vaccines on a pandemic scale as a result of its public-private partnership with the Biomedical Advanced Research and Development Authority.